From the $LXRP FAQ: Is Lexaria In the Oil Biz or the
From the $LXRP FAQ: Is Lexaria In the Oil Biz or the Marijuana Biz?
For now: both. We're focusing on the marijuana sector and that's where we expect our major growth. Meanwhile, we have valuable assets in the oil sector that generate revenue for us every month. Until we dispose of those assets, or until they stop giving us cash flow, it makes sense to extract as much value from them as we can. As of October 31, 2013, our reserve report filed with the Securities and Exchange Commission says that our Proved Reserves will generate $5,985,869 NET cash flows over their life to Lexaria, discounted at 10% per annum.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding Oscar Health's Recent Options Activity In the fast-paced world of trading, Oscar Health Inc’s (NYSE: OSCR) recent options activity has captured significant attention among savvy investors. Notably, there has been a notable bullish sentiment from wealthy investors towards this health insurance company. Tracking public options data reveals movements that...
Continue Reading
Better Choice Company Settles on Halo Asia Sale Better Choice Company, Inc. (BTTR), a leader in pet health and wellness, has recently reached a significant milestone by signing a definitive agreement to sell its Halo business in Asia. This sale is projected to generate total gross proceeds of $8.1 million, which encompasses $6.5 million in cash at the closing of the deal....
Continue Reading
Fastenal Prepares for Earnings Report Fastenal (NASDAQ: FAST) is gearing up to release its quarterly earnings report. Investors are keenly anticipating the upcoming announcement, as it offers a glimpse into the company's financial performance. This article provides essential insights and analysis for those eager to understand what to expect from Fastenal's announcement....
Continue Reading
Compass Therapeutics Advances Cancer Research BOSTON — Compass Therapeutics, Inc. (Nasdaq: CMPX), a promising player in the biotechnology sphere focused on developing innovative therapies for cancer, has made significant strides in its clinical research. The company has announced that the first patient has been dosed in a groundbreaking Investigator Sponsored Trial...
Continue Reading
Overview of the ECB Fine Imposed on LHV Group The European Central Bank (ECB) has recently informed AS LHV Group about a decision to levy an administrative fine amounting to EUR 405 thousand. This fine is linked to an error identified in the consolidated regulatory reporting for a specified timeframe. The issue arose from discrepancies in how the equity of LHV Bank...
Continue Reading
